Freiburg, Germany
CYTENA, founded in 2014 and headquartered in Germany, specializes in optimizing the development of biotherapeutic drugs through innovative microtechnology. A highlight of their product offerings includes the automated isolation of single cells with assured clonality, which is crucial for developing promising therapies. Their instruments are not only precise but also compatible with various cell types, featuring high viability rates and preventing cross-contamination with disposable cartridges.
The company has already penetrated the market successfully, gaining traction among major players. Specifically, most of the top ten largest pharmaceutical companies have adopted CYTENA instruments, integrating them into workflows to enhance monoclonal cell lines crucial for antibody development. Furthermore, their tools are versatile enough for academic research, including studies focused on cancer, autoimmune diseases, and genomics.
CYTENA attracted significant attention when acquired by CELLINK in 2019 with a transaction valued at €30.25M. Their slogan, "We make the development of modern therapies faster, safer, and more affordable," underscores their visionary focus on enhancing health sciences.
